Skip to main content
. 2023 Oct 13;16:6703–6715. doi: 10.2147/IDR.S424345

Table 4.

A Systematic Review of Antibiotic Resistance of Salmonella Among Asymptomatic Food Handlers and Public Health Facility Diarrheic Patients in Ethiopia from January 1, 2010 to December 30, 2022

Authors name, Number of isolates and Reference Antibiotics Resistance, n (%)
AMO AMP T SXT C NA CN CIP CRO
Food handlers
Gebreyesus et al (n=3)31 ND 2 (66.7) 2 (66.7) ND 3 (100) ND 0 0 ND
Getie et al (n=3)32 1 (33.3) 0 2 (66.7) 1 (33.3) 0 0 1 (33.3) 0 0
Abera et al (n=6)33 ND 6 (100) 4 (66.7) 5 (83.3) 2 (33.3) ND 2 (33.3) ND ND
Solomon et al (n=35)34 26 (74.3) 30 (85.7) ND 24 (68.6) 9 (25.7) 15 (42.9) ND 5 (14.3) 10 (28.6)
Awol et al (n=5)35 Nr 3 (60) 4 (80) 2 (40) 2 (40) 1 (20) ND 0 0
Yesigat et al (n=6)36 ND 6 (100) 5 (83.3) 1 (16.7) 0 ND ND 0 ND
Aklilu et al (n=6)37 6 (100) 6 (100) 0 ND ND ND 0 0 ND
Kifelew et al (n=13)38 6 (46.2) 7 (53.8) 6 (42.3) 2 (15.4) ND 2 (15.4) 0 ND 0
Getnet et al (n=8)39 ND 7 (87.5) 1 (12.5) 1 (12.5) 1 (12.5) Nr 0 1 (12.5) 0
Mengist et al (n=8)40 ND 8 (100) 5 (83.3) 3 (37.5) 2 (25) ND 0 0 ND
Tadesse et al (n=13)41 12 (92.3) 12 (92.3) 10 (77) 2 (15.4) 1 (7.7) 2 (15.4) 2 (15.4) 0 0
Mama and Alemu (n=24)42 24 (100) ND ND 0 0 ND 0 ND 0
Diriba et al (n=21)43 15 (71.4) 17 (81) ND 10 (47.6) 15 (71) ND ND 5 (23.8) 3 (100)
Diarrheic patients
Tosisa et al (n=3)44 0 3 (100) 2 (66.7) 2 (66.7) 1 (33.3) 0 0 0 ND
Abebe et al (n=2)45 ND 2 (100) ND 1 (50) 0 0 2 (100) 0 0
Getamesay et al (n=4)46 0 0 0 0 0 1 (25) 0 0 4 (100)
Mamuye et al (n=10)47 8 (80) 8 (80) ND 6 (60) 4 (40) 2 (20) 0 0 0
Mulu et al (n=24)48 8 (33.3) 22 (91.7) 0 8 (33.3) 4 (16.7) ND ND 4 (16.7) 9 (37.5)
Kebede et al (n=11)49 ND ND 7 (63.7) 8 (72.7) 8 (72.7) 1 (9) 1 (9) 1 (9) 1 (9)
Amsalu et al (n=8)50 ND ND 7 (87.5) 7 (87.5) 4 (50) 3 (37.5) 2 (25) 1 (12.5) 2 (25)
Beyene and Tasew (n=16)51 16 (100) 10 (62.5) ND 5 (31.3) 3 (18.8) 2 (12.5) 0 0 0
Eguale et al, 201552

  • S. Typhimurium (n=27)

 4 (14.8) 6 (22.2) 3 (11.1) 1 (3.7) 1 (3.7) 0 (0) 0 (0) 0 (0) 1 (3.7)

  • S. Newport (n=2)

 1 (50) 1 (50) 0 (0) 1 (50) 0 (0) 1 (50) 0 (0) 0 (0) 0 (0)

  • S. Virchow (n=21)

 1 (4.8) 1 (4.8) 3 (14.3) 0 (0) 0 (0) 10 (47.6) 0 (0) 0 (0) 0 (0)

  • S. Kottbus (n=7)

 0 (0) 0 (0) 1 (14.3) 0 (0) 1 (14.3) 0 (0) 0 (0) 1 (14.3) 0 (0)

  • S. Enteritidis (n=1)

 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

  • S. Braenderup (n=1)

 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

  • S. Concord (n=1)

 1 (100) 1 (100) 1 (100) 1 (100) 0 (0) 0 (0) 1 (100) 1 (100) 0 (0)

  • S. Miami (n=3)

 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

  • S. Kentucky (n=2)

 2 (100) 2 (100) 2 (100) 2 (100) 0 (0) 2 (100) 2 (100) 2 (100) 0 (0)
Gebregziabher et al (n=19)53 ND 17 (89.5) 17 (89.5) 11 (57.9) 15 (78.9) 6 (31.6) 3 (15.8) 0 2 (10.5)
Terfassa et al (n=30)54 27 (90) ND ND ND 2 (6.6) 1 (3.3) 3 (10) 2 (6.7) 1 (3.3)
Asefa et al (n=29)55 29 (100) ND 23 (79) ND 9 (31) ND ND 0 0
Lamboro et al (n=19)56 ND 19 (100) 9 (47.6) 1 (5.3) 1 (5.3) 5 (26.3) 1 (5.3) 0 ND
Reda et al (28)57 28 (100) 28 (100) 20 (71.4) ND 18 (64.3) ND 1 (3.6) ND ND
Ameya et al (21)58 21 (100) ND ND 8 (38.1) 9 (42.9) ND 4 (19) 0 ND

Abbreviations: AMP, Ampicillin; AMO, Amoxicillin; SXT, sulfamethoxazole-trimethoprim; NA, Nalidixic acid; CRO, Ceftriaxone; CIP, Ciprofloxacin; C, Chloramphenicol; CN, Gentamicin; T, Tetracycline; ND, Not Done.